Chemistry: molecular biology and microbiology – Measuring or testing process involving enzymes or... – Involving antigen-antibody binding – specific binding protein...
Reexamination Certificate
2000-03-20
2008-09-02
Fetterolf, Brandon J (Department: 1642)
Chemistry: molecular biology and microbiology
Measuring or testing process involving enzymes or...
Involving antigen-antibody binding, specific binding protein...
C530S387900, C530S388100, C530S388800, C530S389100, C530S391300
Reexamination Certificate
active
07419794
ABSTRACT:
Antibodies that can specially bind to cytochrome P450 CYP1B1 and methods of making them are disclosed, in particular antibodies that bind to amino acid sequence VNQWSVNHDPVKWPN or PExFDPARFLDKDGy, where x is D or N and y is L or F, or an antigenic fragment thereof. The antibodies can be used in the diagnosis or treatment of cancers linked to enhanced CYP1B1 expression, including breast cancer, prostate cancer, colorectal cancer, liver cancer and ovarian cancer.
REFERENCES:
patent: 5688773 (1997-11-01), Chiocca et al.
patent: 6242203 (2001-06-01), Melvin et al.
patent: 6824780 (2004-11-01), Devaux et al.
patent: WO 9007861 (1990-07-01), None
patent: WO 97/12246 (1997-04-01), None
patent: WO 9712246 (1997-04-01), None
Pottenger et al. (Arch. Biochem. Biophys. 1991; 286: 488-497).
Jain (Scientific American Jul. 1994).
Dillman (Annals on Internal Medicine, vol. 111, pp. 592-603, 1989).
Weiner (Seminars Oncology, vol. 26, No. 4, 1999, pp. 41-50).
Gura (Science, v278, 1997, pp. 1041-1042).
Kettleborough et al. (Protein Engineering 1991; 4: 773-783).
Cambell, A.M. (Monoclonal Antibody Technology, Elsevier Science, NY, 1986, pp. 1-33).
Bailey et al. (1998) “Association of cytochrome P450 1B1 (CYP1B1)polymorphism with steroid receptor status in breast cancer”Cancer Research58(22):5038-41.
Bhattacharyya et al. (1995) “Identification of a Rat Adrenal Cytochrome P450 Active in Polycyclic Hydrocarbon Metabolism as Rat CYP1B1”J. Biol. Chem.,270:11595-602.
Crespl et al. (1997) “Development of a human lyphoblastoid cell line constituitively expressing human CYP1B1 cDNA: substrate specificity with model substrates and promutagens”Mutagenesis, 12(2):83-9.
Duncan et al. (1992) “A simple enzyme linked immunosorbent assay (ELISA) for the neuron-specific γ isozyme of human enolase (NSE) using monoclonal antibodies raised against synthetic peptides corresponding to isozyme sequence differences.”J. Immunol. Meth.151:227-36.
Elston & Ellis (1991) “Pathelogical prognostic factors in breast cancer. I. The value of histological grade in breast cancer: experience from a large study with long-term follow-up.”Histopathology, 19:403-410.
Hakkola et al. (1997) “Expression of CYP1B1 in human adult and fetal tissues and differential inducibility of CYP1B1 and CYP1A1 by Ah receptor ligands in human placenta and cultured cells.”Carinogensis18:391-97.
Hayes et al. (1996) “17 beta-estradiol hydroxylation catalyzed by human cytochrome P450 1B1”PNAS, USA93(18):9776-81.
King et al. (1997) “A highly senstive detection method for immunohistochemistry using biotinylated tyramine.”J. Pathol.183:237-41.
Liehr and Ricci (1996) “4-hydroxylation of estrogens as markers of human mammary tumors”PNAS, USA93(8):3294-6.
McKay, J. et al. (1995) “Expression of cytochrome P450 CYP1B1 in breast cancer”FEBS Letters, 374:270-2.
Murray et al. (1997) “Tumor-specific expression of cytochrome P450 CYP1B1”.Cancer Research57:3026-31.
Murray et al. (1998) “Matrix metalloproteinase-1 is associated with poor prognosis in eosophageal cancer.”J. Pathol.185:256-61.
Murray et al. (1998) “Matrix metalloproteinases and their inhibitors in gastric cancer.”Gut,43:791-797.
Savas et al. (1994)“Mouse Cytochrome P-450EF, Representative of a New 1B Subfamily of Cytochrome P-450's”J. Biol. Chem.269:14905-11.
Savas et al. (1997) “Biological Oxidation and P450 Reactions”Arch. Biochem. Biophys., 347:181-92.
Schmidt & Bradfield (1996) “AH Receptor Signaling Pathways.”Annu. Rev. Cell Dev. Biol.12:55-89.
Shen et al. (1994) “cDNA Cloning, Sequence Analysis, and Induction by Aryl Hydrocarbons of aMurine Cytochrome P450 Gene, Cyb1b1.”DNA Cell Biol.13:763-9.
Shimada et al. (1996) “Activation of chemically diverse procarcinogens by human cytochrome P450 1B1”Cancer Research56(13):2979-84.
Sutter et al. (1994) “Complete cDNA Sequence of a Human Dioxin-inducible mRNA Identifies a New Gene Subfamily of Cytochrome P450 That Maps to Chromosome 2.”J. Biol.Chem.269:13092-9.
Tailor, G. et al. (1998) “Detection of cytochrome P450 CYP1B1 in human tumors using monoclonal antibodies against a c-terminal decapeptide” Human & Experimental Toxicology, vol. 17, No. 9, pp. 534. Proceedings of the British Toxicology Society Annual Congress Guilford, England, UK Apr. 19-22, 1998.British Tocicological Society, abstract.
Tang et al. (1996) “Isolation and Characterization of the Human Cytochrome P450 CYP1B1 Gene.”J. Biol. Chem.,271:28324-30.
Tang et al. (1999) “Development of an antipeptide antibody that binds to the C-terminal region of human CYP1B1”Drug Metabolism and Disposition(Feb. 1999) 27(2):274-80, abstract.
Walker et al. (1995) “Rat CYP1B1: an adrenal cytochrome P450 that exhibits sex-dependent expression in livers and kidneys of TCDD-treated animals.”Carcinogenesis, 16:1319-27.
Wang et al. (1998) “Functional and physical interactions between the estrogen receptor Sp1 and nuclear aryl hydrocarbon receptor complexes.” Nucl. Acid. Res. 26:3044-52.
Melvin William
Murray Graeme Ian
Baker Gary
Fetterolf Brandon J
Quine Intellectual Property Law Group
University Court of the University of Aberdeen
LandOfFree
Antibodies specific for CYP1B1 does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Antibodies specific for CYP1B1, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Antibodies specific for CYP1B1 will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3979480